ES2310860T3 - Profarmaco amida de gemcitabina, composiciones y uso del mismo. - Google Patents

Profarmaco amida de gemcitabina, composiciones y uso del mismo. Download PDF

Info

Publication number
ES2310860T3
ES2310860T3 ES05852411T ES05852411T ES2310860T3 ES 2310860 T3 ES2310860 T3 ES 2310860T3 ES 05852411 T ES05852411 T ES 05852411T ES 05852411 T ES05852411 T ES 05852411T ES 2310860 T3 ES2310860 T3 ES 2310860T3
Authority
ES
Spain
Prior art keywords
compound
gemcitabine
formula
cancer
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05852411T
Other languages
English (en)
Spanish (es)
Inventor
David Michael Bender
David Michael Remick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2310860T3 publication Critical patent/ES2310860T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
ES05852411T 2004-12-17 2005-11-30 Profarmaco amida de gemcitabina, composiciones y uso del mismo. Expired - Lifetime ES2310860T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63742204P 2004-12-17 2004-12-17
US637422P 2004-12-17

Publications (1)

Publication Number Publication Date
ES2310860T3 true ES2310860T3 (es) 2009-01-16

Family

ID=36168678

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05852411T Expired - Lifetime ES2310860T3 (es) 2004-12-17 2005-11-30 Profarmaco amida de gemcitabina, composiciones y uso del mismo.

Country Status (31)

Country Link
US (1) US7691827B2 (enExample)
EP (1) EP1831237B1 (enExample)
JP (1) JP5022911B2 (enExample)
KR (1) KR100874052B1 (enExample)
CN (1) CN101080417B (enExample)
AR (1) AR055009A1 (enExample)
AT (1) ATE405573T1 (enExample)
AU (1) AU2005316922B2 (enExample)
BR (1) BRPI0519117A2 (enExample)
CA (1) CA2589850C (enExample)
CY (1) CY1108447T1 (enExample)
DE (1) DE602005009255D1 (enExample)
DK (1) DK1831237T3 (enExample)
EA (1) EA011868B1 (enExample)
ES (1) ES2310860T3 (enExample)
HR (1) HRP20080529T3 (enExample)
IL (1) IL183666A (enExample)
MA (1) MA29154B1 (enExample)
MX (1) MX2007007228A (enExample)
MY (1) MY143677A (enExample)
NO (1) NO20073368L (enExample)
NZ (1) NZ554732A (enExample)
PE (1) PE20060771A1 (enExample)
PL (1) PL1831237T3 (enExample)
PT (1) PT1831237E (enExample)
RS (1) RS50629B (enExample)
SI (1) SI1831237T1 (enExample)
TW (1) TWI326687B (enExample)
UA (1) UA86119C2 (enExample)
WO (1) WO2006065525A1 (enExample)
ZA (1) ZA200705019B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007149891A2 (en) * 2006-06-21 2007-12-27 Eli Lilly And Company Crystalline forms of gemcitabine amide prodrug, compositions and use thereof
TWI436775B (zh) 2007-08-24 2014-05-11 Oncotherapy Science Inc 以抗原胜肽合併化療藥劑治療胰臟癌
CN101525361B (zh) * 2009-04-21 2010-11-17 济南圣鲁金药物技术开发有限公司 基于吉西他滨结构的前药及其合成方法及应用
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
CN102432654A (zh) * 2011-09-26 2012-05-02 宋云龙 吉西他滨酰胺衍生物及其制备方法和用途
CA2890359A1 (en) 2012-11-07 2014-05-15 Zucai SUO Substituted gemcitabine aryl amide analogs and treatment methods using same
WO2014078295A1 (en) 2012-11-13 2014-05-22 BoYen Therapeutics, Inc. Gemcitabine prodrugs and uses thereof
CN106459130A (zh) * 2014-03-03 2017-02-22 纽科利制药公司 吉西他滨类似物
WO2016078160A1 (zh) * 2014-11-17 2016-05-26 常州方圆制药有限公司 胞苷衍生物及其应用
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
EP3752511A4 (en) 2018-01-10 2021-12-29 Nucorion Pharmaceuticals, Inc. Phosphor(n)amidatacetal and phosph(on)atalcetal compounds
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
AU2019216531A1 (en) 2018-02-02 2020-09-24 Maverix Oncology, Inc. Small molecule drug conjugates of gemcitabine monophosphate
JP7598313B2 (ja) * 2018-04-26 2024-12-11 ナノメッド ホールディングス プロプライエタリー リミテッド ジェムシタビン両親媒性プロドラッグ
CN108864250A (zh) * 2018-05-29 2018-11-23 北京大学 一种FAPα酶敏感的吉西他滨前体药物及其制备方法和应用
US20210171564A1 (en) * 2018-08-03 2021-06-10 Cellix Bio Provate Limited Compositions and methods for the treatment of cancer
MX2022000573A (es) 2019-07-17 2022-02-10 Nucorion Pharmaceuticals Inc Compuestos ciclicos de desoxirribonucleotido.
KR20230004716A (ko) 2020-04-21 2023-01-06 리간드 파마슈티칼스 인코포레이티드 뉴클레오티드 프로드러그 화합물
PL442924A1 (pl) * 2022-11-23 2024-05-27 Politechnika Śląska Prolek - glikokoniugat pochodny gemcytabiny, jako związek o działaniu przeciwnowotworowym, sposób otrzymywania i zastosowanie

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
US4965374A (en) * 1987-08-28 1990-10-23 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
RU2131880C1 (ru) * 1992-06-22 1999-06-20 Эли Лилли Энд Компани Способ получения обогащенных бета-аномером нуклеозидов
YU43193A (sh) * 1992-06-22 1997-01-08 Eli Lilly And Company 2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi
GB2321454A (en) * 1997-01-24 1998-07-29 Norsk Hydro As Gemcitabine esters and amides
ATE236188T1 (de) * 1997-01-24 2003-04-15 Conpharma As Gemcitabin-derivate
US6624142B2 (en) * 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US5965119A (en) * 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US6376470B1 (en) * 1999-09-23 2002-04-23 Enzon, Inc. Polymer conjugates of ara-C and ara-C derivatives
US7265096B2 (en) * 2002-11-04 2007-09-04 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
US7846436B2 (en) * 2003-11-28 2010-12-07 Chemgenes Corporation Oligonucleotides and related compounds

Also Published As

Publication number Publication date
IL183666A0 (en) 2007-09-20
AU2005316922A1 (en) 2006-06-22
KR100874052B1 (ko) 2008-12-12
EP1831237A1 (en) 2007-09-12
PT1831237E (pt) 2008-09-22
TWI326687B (en) 2010-07-01
CY1108447T1 (el) 2014-04-09
BRPI0519117A2 (pt) 2008-12-23
NZ554732A (en) 2010-09-30
AR055009A1 (es) 2007-08-01
SI1831237T1 (sl) 2009-02-28
RS50629B (sr) 2010-06-30
NO20073368L (no) 2007-07-16
CN101080417B (zh) 2011-01-19
US20090156547A1 (en) 2009-06-18
US7691827B2 (en) 2010-04-06
EA200701300A1 (ru) 2007-10-26
DE602005009255D1 (de) 2008-10-02
ZA200705019B (en) 2008-10-29
KR20070086308A (ko) 2007-08-27
CA2589850C (en) 2012-05-01
EP1831237B1 (en) 2008-08-20
ATE405573T1 (de) 2008-09-15
DK1831237T3 (da) 2008-10-27
MY143677A (en) 2011-06-30
CN101080417A (zh) 2007-11-28
EA011868B1 (ru) 2009-06-30
AU2005316922B2 (en) 2011-08-25
JP2008524218A (ja) 2008-07-10
TW200634023A (en) 2006-10-01
MX2007007228A (es) 2007-08-14
UA86119C2 (ru) 2009-03-25
WO2006065525A1 (en) 2006-06-22
PE20060771A1 (es) 2006-09-23
JP5022911B2 (ja) 2012-09-12
HK1109903A1 (en) 2008-06-27
MA29154B1 (fr) 2008-01-02
IL183666A (en) 2011-09-27
CA2589850A1 (en) 2006-06-22
PL1831237T3 (pl) 2009-01-30
HRP20080529T3 (en) 2008-12-31

Similar Documents

Publication Publication Date Title
ES2310860T3 (es) Profarmaco amida de gemcitabina, composiciones y uso del mismo.
ES2577514T3 (es) Antagonistas de TLR
ES2446092T3 (es) Formas cristalinas del profármaco amida gemcitabina, composiciones y uso de las mismas
ES2746105T3 (es) Profármacos de 5-aza-pirimidina sililada útiles para tratar el cáncer
CA2926909A1 (en) Mutual prodrug comprising short chain fatty acids and zebularine or 1'-cyano-cytarabine for cancer treatment
KR101093787B1 (ko) 신규한 뉴클레오시드 유도체를 포함하는 암 치료용 약학적 조성물
WO2022140705A1 (en) Prodrugs of pharmaceutical agents
EP3470403B1 (en) Taxoid compound and preparation method and use thereof
HK1109903B (en) Amide prodrug of gemcitabine, compositions and use thereof
CN118852283A (zh) 防治肿瘤的化合物及其制备方法和应用
BRPI0713615A2 (pt) Formas cristalinas de pró-fármacos de amida de gemcitabina, composições de uso das mesmas
HK1116197A (en) Amide prodrug of gemcitabine, compositions and use thereof